ストックスクリーナーアプリを入手
22.52
1.49%
0.33
前日終値:
$22.19
開ける：
$22.26
24時間の取引高:
720.85K
Relative Volume:
0.57
時価総額：
$2.78B
収益：
$460.48M
当期純損益:
$142.80M
株価収益率:
19.08
EPS:
1.18
ネットキャッシュフロー:
$221.79M
1週間 パフォーマンス:
+4.99%
1か月 パフォーマンス:
+3.26%
6か月 パフォーマンス:
+6.43%
1年 パフォーマンス:
+40.75%
1日の値動き範囲:
$22.14
$22.67
1週間の範囲:
$21.04
$23.27
52週間の値動き範囲:
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
名前
Catalyst Pharmaceuticals Inc
セクター
電話
(305) 529-2522
住所
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.52 | 2.78B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-03-14 | 開始されました | Citigroup | Buy |
| 2024-03-07 | 開始されました | BofA Securities | Buy |
| 2023-12-21 | 開始されました | Oppenheimer | Outperform |
| 2022-08-24 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 再開されました | Piper Jaffray | Overweight |
| 2016-10-05 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2013-10-21 | 繰り返されました | Aegis Capital | Buy |
| 2013-09-24 | 開始されました | Maxim Group | Buy |
| 2013-09-06 | 繰り返されました | Aegis Capital | Buy |
| 2013-04-18 | 開始されました | Aegis Capital | Buy |
| 2012-08-27 | アップグレード | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | アップグレード | Merriman | Sell → Neutral |
| 2009-05-29 | ダウングレード | Hapoalim | Neutral → Underperform |
| 2009-05-29 | ダウングレード | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 開始されました | Merriman Curhan Ford | Buy |
| 2007-11-28 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 開始されました | Stifel Nicolaus | Buy |
| 2007-01-05 | 開始されました | First Albany | Buy |
すべてを表示
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - Insider Monkey
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance
Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com
Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire
First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - Quantisnow
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals - The Manila Times
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN
Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN
Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st
CPRX stock soars to all-time high of $24.8 amid robust growth - Investing.com
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
Catalyst Pharmaceuticals Inc (CPRX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):